Chief Executive Officer & Founder
Mary E. Dixon is the Chief Executive Officer and Founder of Innovenn, Inc., a life sciences consulting firm focused on advancing precision medicine and digital health innovation. With more than 30 years of experience in the pharmaceutical and biotechnology industries, Mary brings deep expertise in strategy, regulatory development, and cross-functional leadership to organizations developing breakthrough therapies and technologies. Notably, she has contributed to the development of 15 marketed compounds across various clinical domains, including pain management, reproductive health, and mental health disorders like schizophrenia and Alzheimer’s.
Mary’s entrepreneurial journey began in 2006, after launching her first consulting company to support pharmaceutical development strategy. As she celebrates 20 years of building and scaling life science consulting organizations, she continues to guide Innovenn’s mission of accelerating innovation that improves patient outcomes.
Today, Innovenn’s team collectively brings 250+ years of combined industry experience, working alongside global pharmaceutical companies, emerging biotech innovators, and digital health developers to create regulatory-ready solutions that advance precision medicine. Mary excels in aligning short-term objectives with long-term goals, motivating teams, and ensuring operational alignment with the company’s mission. By forging strategic partnerships and driving innovation, Innovenn is positioned as a leader in healthcare innovation, dedicated to addressing unmet patient needs and enhancing healthcare delivery.
Mary E. Dixon’s leadership is instrumental in driving success and positively impacting healthcare innovation and patient care.
Chair of the Board
As Chair of the Board of Innovenn, Mary E. Dixon provides strategic oversight and governance for the company’s continued growth and impact in the life sciences sector. In her role, she collaborates closely with the board members to establish clear goals and priorities aligned with the company’s mission and objectives. Mary ensures corporate integrity and compliance with regulations, leading board meetings and fostering open dialogue among members.
Her leadership emphasizes responsible governance, risk management, and strategic partnerships that enable Innovenn to expand its influence in precision medicine, digital health technologies, and regulated medical innovation.
Committed to fostering a culture of innovation, collaboration, and ethical behavior, Mary plays a pivotal role in Innovenn’s success, driving growth and creating long-term value for stakeholders.
